# Oral vitamin C × first gout diagnosis in men without gout

Verdict 3020 · Evidence Check

Stored-material review date: Not recorded  
Original evidence cut-off: 2026-09-07  
Review-criteria version: 1.0  
Public page/material preparation date: 2026-10-22

Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect.

## Assessment scope

- Population: This concerns the analysis of men without prior gout. The original PHS II involved male physicians≥50 years; its full cohort included6.5% with prior gout and is distinguished from the prior-gout-excluded analysis.
- Ingredient, formulation and route: The parent’s oral single-ingredient ascorbic acid context is retained. Exact product, tablet/capsule, salt, excipients and actual exposure in the selected analysis remain unverified. Foods, combinations and intravenous infusion are not automatically included.
- Dose: The exact dose for the selected PHS II analysis is absent from this stored account. The parent’s not-applicable dose for absent eligible recurrent-flare studies is not transferred to this question or filled using external knowledge.
- Comparator: C versus placebo in the original factorial trial is distinguished from full allocation and the prior-gout-excluded analysis. Other factors, drugs, additional supplementation, adherence and crossover details remain unverified; this is not a standard gout-drug replacement trial.
- Measured outcome: This is a post hoc analysis of annually self-reported first gout diagnoses. It is distinguished from actual attack frequency, recurrence and urate reduction. First-event ascertainment, clinical confirmation and date-imputation details remain unverified.
- Duration: The account describes a long-term factorial trial and annual diagnosis reports. Exact dosing, follow-up, person-year denominators, exposure changes and post-stopping follow-up remain unverified in this stored account.
- Questions outside this scope: The selected D30 verdict is retained. The parent verdict on recurrent-flare prevention in established gout is deferred with an empty score; parent assessment axes are not inherited by the selected question.; The prior-gout-excluded262/6865 versus290/6823, HR0.90(95%CI0.76–1.07),P=.23 and rates4.8 versus5.4/1000 person-years are retained. Nonsignificance is not relabeled as an effect of 0 or equivalence, and no new effect, interval or person-years are calculated.; The full-cohort454/7329 versus517/7312, HR0.88(95%CI0.77–0.99),P=.04 is separate context including prior gout. It does not replace the selected analysis’s uncertain result, and the analyses are not summed as independent trials or new participants.; Exposure allocation in the original randomized double-blind factorial trial is distinguished from the post hoc gout outcome. NCT00270647 for the original cardiovascular/cancer trial does not establish gout prespecification or reading of the official registration history.; The parent’s no-human-study indicator is true, while its narrative says it should be false because human studies exist. This disagreement is preserved without correction or inheritance by the selected question in this production.; First diagnosis reports, recurrent attacks in established gout, serum urate and replacement of standard medication are separate questions. Existing caution for high oral doses, gastrointestinal effects, stone risk, kidney disease and iron overload is retained without new safety conclusions, incidence estimates or individual dosing guidance.

## Checklist items

### N01 · What is the selected question?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The selected wording is “First gout diagnosis in men without gout.” The existing subclaim is linked separately from its verdict record.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The parent question on recurrent-flare prevention in established gout is not repurposed as this question or made into a new claim.
- Required materials and conditions: Existing subclaim and verdict record, and the parent-question boundary
- Materials to obtain first: The parent question on recurrent-flare prevention in established gout is not repurposed as this question or made into a new claim.
- Further research: Material needed: The parent question on recurrent-flare prevention in established gout is not repurposed as this question or made into a new claim. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Existing subclaim and verdict record, and the parent-question boundary must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Existing subclaim and verdict record, and the parent-question boundary is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N02 · What do selected D30 and parent deferral mean?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The selected D·30 score is retained. The parent verdict is deferred with an empty score and unscored evidence axes.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The verdicts are not overwritten by each other or changed into a new verdict or fulfilled condition.
- Required materials and conditions: Distinguishing selected D30 from parent deferral and empty score
- Materials to obtain first: The verdicts are not overwritten by each other or changed into a new verdict or fulfilled condition.
- Further research: Material needed: The verdicts are not overwritten by each other or changed into a new verdict or fulfilled condition. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Distinguishing selected D30 from parent deferral and empty score must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Distinguishing selected D30 from parent deferral and empty score is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N03 · What materials were read in this work?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The complete Korean and English parent summary, 1 evidence entry, 2 citations and 2 subclaims were read. Historical indexed full-text, table, funding and independent-comparison flags are retained as history.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: External abstracts, full text, registration, protocols and analysis plans are unread and access was not attempted. Historical checks are not inherited as current content review.
- Required materials and conditions: Complete parent summary, subclaims, historical checks and unread external materials
- Materials to obtain first: External abstracts, full text, registration, protocols and analysis plans are unread and access was not attempted. Historical checks are not inherited as current content review.
- Further research: Material needed: External abstracts, full text, registration, protocols and analysis plans are unread and access was not attempted. Historical checks are not inherited as current content review. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Complete parent summary, subclaims, historical checks and unread external materials must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Complete parent summary, subclaims, historical checks and unread external materials is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N04 · What is the post hoc PHS II report?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The post hoc PHS II gout analysis in Am J Clin Nutr2022, PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 is retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The identifier belongs to the original cardiovascular/cancer trial. Gout prespecification is unverified; the original text and registration remain unread in this work.
- Required materials and conditions: Juraschek2022, PMID/PMCID/DOI and original-trial registration
- Materials to obtain first: The identifier belongs to the original cardiovascular/cancer trial. Gout prespecification is unverified; the original text and registration remain unread in this work.
- Further research: Material needed: The identifier belongs to the original cardiovascular/cancer trial. Gout prespecification is unverified; the original text and registration remain unread in this work. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Juraschek2022, PMID/PMCID/DOI and original-trial registration must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Juraschek2022, PMID/PMCID/DOI and original-trial registration is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N05 · Are the original trial and subgroup analyses counted twice?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The full-cohort and prior-gout-excluded analyses are different analyses of the same PHS II data.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: They are not added as independent trials or new participants. Unique trial, participant and replication totals remain unverified.
- Required materials and conditions: Original factorial trial, full-cohort and prior-gout-excluded analyses, and shared participants
- Materials to obtain first: They are not added as independent trials or new participants. Unique trial, participant and replication totals remain unverified.
- Further research: Material needed: They are not added as independent trials or new participants. Unique trial, participant and replication totals remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Original factorial trial, full-cohort and prior-gout-excluded analyses, and shared participants must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Original factorial trial, full-cohort and prior-gout-excluded analyses, and shared participants is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N06 · Who are the men without prior gout?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The original trial involved male physicians≥50 years; its full cohort included6.5% with prior gout. The selected question uses the prior-gout-excluded analysis.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Results are not extended to women, the general population or recurrent attacks in established gout. History ascertainment, detailed selection and baseline balance remain unverified.
- Required materials and conditions: Male physicians≥50 years, prior-gout exclusion, selection and baseline
- Materials to obtain first: Results are not extended to women, the general population or recurrent attacks in established gout. History ascertainment, detailed selection and baseline balance remain unverified.
- Further research: Material needed: Results are not extended to women, the general population or recurrent attacks in established gout. History ascertainment, detailed selection and baseline balance remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Male physicians≥50 years, prior-gout exclusion, selection and baseline must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Male physicians≥50 years, prior-gout exclusion, selection and baseline is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N07 · Are full-cohort diagnosis reports the same as first diagnoses?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The existing explanation is retained: relabeling full-cohort new-diagnosis reports as first onset without prior gout or recurrent attacks changes the event definition.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The positive full-cohort HR is not repurposed as the selected first-diagnosis effect.
- Required materials and conditions: Event definitions in the full cohort including prior gout and the prior-gout-excluded analysis
- Materials to obtain first: The positive full-cohort HR is not repurposed as the selected first-diagnosis effect.
- Further research: Material needed: The positive full-cohort HR is not repurposed as the selected first-diagnosis effect. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Event definitions in the full cohort including prior gout and the prior-gout-excluded analysis must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Event definitions in the full cohort including prior gout and the prior-gout-excluded analysis is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N08 · What is the selected analysis result?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Prior-gout-excluded262/6865 versus290/6823; HR0.90(95%CI0.76–1.07),P=.23; rates4.8 versus5.4/1000 person-years are retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: No new incidence rate, HR, difference or CI is calculated. Nonsignificance is not judged as an effect of0 or equivalence.
- Required materials and conditions: Prior-gout-excluded events, denominators, HR,95%CI, P and rates
- Materials to obtain first: No new incidence rate, HR, difference or CI is calculated. Nonsignificance is not judged as an effect of0 or equivalence.
- Further research: Material needed: No new incidence rate, HR, difference or CI is calculated. Nonsignificance is not judged as an effect of0 or equivalence. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Prior-gout-excluded events, denominators, HR,95%CI, P and rates must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Prior-gout-excluded events, denominators, HR,95%CI, P and rates is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N09 · Which analysis produced the positive full-cohort result?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Full-cohort454/7329 versus517/7312; HR0.88(95%CI0.77–0.99),P=.04 is retained as separate analysis context.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The positive full-cohort result including prior gout does not replace uncertainty in the selected analysis or establish attack prevention in established gout.
- Required materials and conditions: Full-cohort454/7329 versus517/7312, HR, P and inclusion of prior gout
- Materials to obtain first: The positive full-cohort result including prior gout does not replace uncertainty in the selected analysis or establish attack prevention in established gout.
- Further research: Material needed: The positive full-cohort result including prior gout does not replace uncertainty in the selected analysis or establish attack prevention in established gout. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Full-cohort454/7329 versus517/7312, HR, P and inclusion of prior gout must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Full-cohort454/7329 versus517/7312, HR, P and inclusion of prior gout is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N10 · What does self-reported diagnosis measure?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Gout was a post hoc question concerning annual diagnosis reports, not attack frequency. Existing self-report and date-imputation limitations are retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Medical records, classification criteria, first-diagnosis ascertainment, missing reports, imputation methods and group-specific measurement differences remain unverified.
- Required materials and conditions: Annual diagnosis reports, first-event ascertainment and date imputation
- Materials to obtain first: Medical records, classification criteria, first-diagnosis ascertainment, missing reports, imputation methods and group-specific measurement differences remain unverified.
- Further research: Material needed: Medical records, classification criteria, first-diagnosis ascertainment, missing reports, imputation methods and group-specific measurement differences remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Annual diagnosis reports, first-event ascertainment and date imputation must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Annual diagnosis reports, first-event ascertainment and date imputation is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N11 · Are randomized allocation and the post hoc outcome distinguished?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Data from the original randomized double-blind factorial trial were analysed post hoc for gout.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Randomized exposure is not elevated to a prespecified primary gout outcome or confirmatory prevention trial. Details of post hoc analysis and selection remain unverified.
- Required materials and conditions: Original factorial trial, exposure allocation, post hoc gout outcome and selection
- Materials to obtain first: Randomized exposure is not elevated to a prespecified primary gout outcome or confirmatory prevention trial. Details of post hoc analysis and selection remain unverified.
- Further research: Material needed: Randomized exposure is not elevated to a prespecified primary gout outcome or confirmatory prevention trial. Details of post hoc analysis and selection remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Original factorial trial, exposure allocation, post hoc gout outcome and selection must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Original factorial trial, exposure allocation, post hoc gout outcome and selection is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N12 · What are the oral formulation and actual dose?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The parent’s general oral single-ingredient ascorbic acid context is retained. This stored account lacks exact PHS II dose and product details.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The parent’s not-applicable dose for absent eligible studies is not transferred to this question or filled using external knowledge.
- Required materials and conditions: Oral C product, dose, ingredients and actual exposure in the selected analysis
- Materials to obtain first: The parent’s not-applicable dose for absent eligible studies is not transferred to this question or filled using external knowledge.
- Further research: Material needed: The parent’s not-applicable dose for absent eligible studies is not transferred to this question or filled using external knowledge. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Oral C product, dose, ingredients and actual exposure in the selected analysis must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Oral C product, dose, ingredients and actual exposure in the selected analysis is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N13 · What is known about dosing, follow-up and person-years?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The existing account describes a long-term factorial trial of male physicians and annual diagnosis reports.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Exact dosing and follow-up duration, person-year denominators, exposure changes, stopping and date-imputation details remain unverified. The parent’s not-applicable duration is not transferred here.
- Required materials and conditions: Long-term factorial trial, annual reports, exact exposure, follow-up and attrition
- Materials to obtain first: Exact dosing and follow-up duration, person-year denominators, exposure changes, stopping and date-imputation details remain unverified. The parent’s not-applicable duration is not transferred here.
- Further research: Material needed: Exact dosing and follow-up duration, person-year denominators, exposure changes, stopping and date-imputation details remain unverified. The parent’s not-applicable duration is not transferred here. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Long-term factorial trial, annual reports, exact exposure, follow-up and attrition must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Long-term factorial trial, annual reports, exact exposure, follow-up and attrition is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N14 · What comparisons involve placebo and concurrent factorial interventions?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The original PHS II was a double-blind factorial trial; C7329/placebo7312 allocation is retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Other factors, drugs, diet, supplements, urate medication, adherence, crossover and adjustment remain unverified. This is not a standard gout-drug replacement trial.
- Required materials and conditions: C, placebo, concurrent randomized factors, adherence, drugs and additional supplements
- Materials to obtain first: Other factors, drugs, diet, supplements, urate medication, adherence, crossover and adjustment remain unverified. This is not a standard gout-drug replacement trial.
- Further research: Material needed: Other factors, drugs, diet, supplements, urate medication, adherence, crossover and adjustment remain unverified. This is not a standard gout-drug replacement trial. This records needed materials; no new research was executed.
- Conditions for verification: Original records on C, placebo, concurrent randomized factors, adherence, drugs and additional supplements must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on C, placebo, concurrent randomized factors, adherence, drugs and additional supplements is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N15 · What are the selected denominators, missingness and censoring?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Total14,641, C7329/placebo7312 and prior-gout-excluded6865/6823 are retained separately.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Subgroup denominators are not relabeled as new allocation. Exclusion, missingness, annual responses, censoring and ITT/PP remain unverified.
- Required materials and conditions: Total14641, allocation, prior-gout-excluded6865/6823, events and analysis
- Materials to obtain first: Subgroup denominators are not relabeled as new allocation. Exclusion, missingness, annual responses, censoring and ITT/PP remain unverified.
- Further research: Material needed: Subgroup denominators are not relabeled as new allocation. Exclusion, missingness, annual responses, censoring and ITT/PP remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Total14641, allocation, prior-gout-excluded6865/6823, events and analysis must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Total14641, allocation, prior-gout-excluded6865/6823, events and analysis is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N16 · What are the HR model and clinically important effect?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The selected prior-gout-excluded HR0.90 has a95%CI0.76–1.07 including the null.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Exact model, adjustment, proportional hazards, clinically important difference and power are not newly verified or calculated. This is not converted into complete absence of effect.
- Required materials and conditions: Adjustment, time, proportional hazards, original95%CI and important difference
- Materials to obtain first: Exact model, adjustment, proportional hazards, clinically important difference and power are not newly verified or calculated. This is not converted into complete absence of effect.
- Further research: Material needed: Exact model, adjustment, proportional hazards, clinically important difference and power are not newly verified or calculated. This is not converted into complete absence of effect. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Adjustment, time, proportional hazards, original95%CI and important difference must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Adjustment, time, proportional hazards, original95%CI and important difference is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N17 · Was the gout outcome preregistered?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The original trial’s main questions were cardiovascular disease/cancer; gout was analysed post hoc. Gout prespecification in the registration remains unverified.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The identifier alone does not establish a prespecified prevention outcome or fulfilled analysis condition. Registration, protocols and analysis plans remain unread in this work.
- Required materials and conditions: Original NCT00270647 trial, cardiovascular/cancer outcomes, gout prespecification and analysis plans
- Materials to obtain first: The identifier alone does not establish a prespecified prevention outcome or fulfilled analysis condition. Registration, protocols and analysis plans remain unread in this work.
- Further research: Material needed: The identifier alone does not establish a prespecified prevention outcome or fulfilled analysis condition. Registration, protocols and analysis plans remain unread in this work. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Original NCT00270647 trial, cardiovascular/cancer outcomes, gout prespecification and analysis plans must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Original NCT00270647 trial, cardiovascular/cancer outcomes, gout prespecification and analysis plans is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N18 · Is the chronic-gout review direct evidence for this question?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Dietary interventions for chronic gout2021, PMID34767649, is parent bibliographic context recording that vitamin C trials did not measure attack frequency.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: The review is not repurposed as a new direct trial, new participants or a urate value for first diagnosis in men without gout.
- Required materials and conditions: Citation-only Cochrane2021, unmeasured attacks and population differences
- Materials to obtain first: The review is not repurposed as a new direct trial, new participants or a urate value for first diagnosis in men without gout.
- Further research: Material needed: The review is not repurposed as a new direct trial, new participants or a urate value for first diagnosis in men without gout. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Citation-only Cochrane2021, unmeasured attacks and population differences must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Citation-only Cochrane2021, unmeasured attacks and population differences is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S02

### N19 · Are independent replication and the3019 urate verdict distinguished?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The parent explanation not to import the3019 urate grade is retained. Full-cohort and excluded PHS II analyses are not independent replication.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Trials, reports and participants from other verdicts are not combined. Unique clinical totals and independent replication for the selected question remain unverified.
- Required materials and conditions: PHS II subgroup analyses, the separate3019 surrogate and report relationships
- Materials to obtain first: Trials, reports and participants from other verdicts are not combined. Unique clinical totals and independent replication for the selected question remain unverified.
- Further research: Material needed: Trials, reports and participants from other verdicts are not combined. Unique clinical totals and independent replication for the selected question remain unverified. This records needed materials; no new research was executed.
- Conditions for verification: Original records on PHS II subgroup analyses, the separate3019 surrogate and report relationships must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on PHS II subgroup analyses, the separate3019 surrogate and report relationships is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N20 · What can be extended across history, sex, dose and duration?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The selected population is men without prior gout; the original analysis involved male physicians≥50 years.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: No new generalization is made to women, the general population, established gout, other doses, sustained prevention or subgroup interactions.
- Required materials and conditions: Prior-gout exclusion, male physicians, prespecified subgroups, interactions and other doses
- Materials to obtain first: No new generalization is made to women, the general population, established gout, other doses, sustained prevention or subgroup interactions.
- Further research: Material needed: No new generalization is made to women, the general population, established gout, other doses, sustained prevention or subgroup interactions. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Prior-gout exclusion, male physicians, prespecified subgroups, interactions and other doses must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Prior-gout exclusion, male physicians, prespecified subgroups, interactions and other doses is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N21 · Are diagnoses, attacks, urate and drug replacement different questions?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The existing account explains that urate reduction, attack prevention and standard-drug replacement each require separate evidence.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: First-diagnosis reports are not repurposed as direct attack frequency, urate reduction or replacement of treatment for established gout.
- Required materials and conditions: Selected diagnoses, clinical attacks, surrogate outcomes and standard-drug replacement
- Materials to obtain first: First-diagnosis reports are not repurposed as direct attack frequency, urate reduction or replacement of treatment for established gout.
- Further research: Material needed: First-diagnosis reports are not repurposed as direct attack frequency, urate reduction or replacement of treatment for established gout. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Selected diagnoses, clinical attacks, surrogate outcomes and standard-drug replacement must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Selected diagnoses, clinical attacks, surrogate outcomes and standard-drug replacement is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N22 · What is known about NIH and industry study-agent support?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The existing account of NIH and BASF/Pfizer/DSM study-agent and packaging support→I1 is retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Funding and product support alone do not verify employee authorship, patents, interests, absence of bias or new independent certification.
- Required materials and conditions: NIH, BASF/Pfizer/DSM, study agents, packaging, employment and interests
- Materials to obtain first: Funding and product support alone do not verify employee authorship, patents, interests, absence of bias or new independent certification.
- Further research: Material needed: Funding and product support alone do not verify employee authorship, patents, interests, absence of bias or new independent certification. This records needed materials; no new research was executed.
- Conditions for verification: Original records on NIH, BASF/Pfizer/DSM, study agents, packaging, employment and interests must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on NIH, BASF/Pfizer/DSM, study agents, packaging, employment and interests is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N23 · How were oral C harms actually collected?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The parent’s caution, high-dose oral gastrointestinal effects and limited event-count wording are retained as context.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Group-specific harms, stopping, exposure denominators and collection in PHS II and the selected analysis remain unverified. Diagnosis results are not used to judge safety.
- Required materials and conditions: Events, collection, stopping, denominators and duration for the selected exposure
- Materials to obtain first: Group-specific harms, stopping, exposure denominators and collection in PHS II and the selected analysis remain unverified. Diagnosis results are not used to judge safety.
- Further research: Material needed: Group-specific harms, stopping, exposure denominators and collection in PHS II and the selected analysis remain unverified. Diagnosis results are not used to judge safety. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Events, collection, stopping, denominators and duration for the selected exposure must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Events, collection, stopping, denominators and duration for the selected exposure is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N24 · What is known about concomitant exposures, predisposition and long-term harms?

Verification status: Unverified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Existing oral caution and the boundaries of product and baseline predisposition are retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Specific interactions, between-group risks, causality, recovery after stopping and absence of long-term or rare harms remain unverified. No new incidence rate or verdict is created.
- Required materials and conditions: Kidney disease, stones, iron overload, concurrent factors, drugs, timelines, long-term and rare events
- Materials to obtain first: Specific interactions, between-group risks, causality, recovery after stopping and absence of long-term or rare harms remain unverified. No new incidence rate or verdict is created.
- Further research: Material needed: Specific interactions, between-group risks, causality, recovery after stopping and absence of long-term or rare harms remain unverified. No new incidence rate or verdict is created. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Kidney disease, stones, iron overload, concurrent factors, drugs, timelines, long-term and rare events must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Kidney disease, stones, iron overload, concurrent factors, drugs, timelines, long-term and rare events is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01

### N25 · Do the parent’s human-study indicator and narrative agree?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: The parent’s no-human-study indicator is enabled, while its narrative says human studies exist and the indicator should be disabled. Both original records are retained.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Neither is corrected as the right answer or inherited as a selected-subclaim axis in this production. Parent axes remain separate from selected D30.
- Required materials and conditions: Disagreement between parent indicator and narrative, and absent selected-subclaim axes
- Materials to obtain first: Neither is corrected as the right answer or inherited as a selected-subclaim axis in this production. Parent axes remain separate from selected D30.
- Further research: Material needed: Neither is corrected as the right answer or inherited as a selected-subclaim axis in this production. Parent axes remain separate from selected D30. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Disagreement between parent indicator and narrative, and absent selected-subclaim axes must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Disagreement between parent indicator and narrative, and absent selected-subclaim axes is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

### N26 · What do Korean/English text, parent dates and empty corrections mean?

Verification status: Partly verified  
Reading scope: Existing Korean and English review summary, question and bibliography read; external abstracts, full text, registration, protocols and analysis plans unread

- Current findings: Selected Korean/English wording and D30, parent deferral, empty score, Korean/English text,2026-09-07 and empty correction/deliberation records are retained. Production date is distinguished from completed content review.
- Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence.
- Reason for missing information: Historical independent checks and the original verdict date are not inherited as current content review or new literature reading. Empty corrections do not establish integrity of all literature.
- Required materials and conditions: Korean/English subclaim text, parent account,2026-09-07 and historical records
- Materials to obtain first: Historical independent checks and the original verdict date are not inherited as current content review or new literature reading. Empty corrections do not establish integrity of all literature.
- Further research: Material needed: Historical independent checks and the original verdict date are not inherited as current content review or new literature reading. Empty corrections do not establish integrity of all literature. This records needed materials; no new research was executed.
- Conditions for verification: Original records on Korean/English subclaim text, parent account,2026-09-07 and historical records must link to the same population, exposure, comparison, event, time point and denominator, distinguishing full-cohort and prior-gout-excluded analyses and diagnoses from attacks.
- Why this condition is needed: Material on Korean/English subclaim text, parent account,2026-09-07 and historical records is needed to connect prior history, sex, oral exposure, comparisons, first diagnosis reports, denominators, precision and harms.
- Application exceptions: The existing selected D30 verdict is preserved separately from the parent’s deferred verdict, empty score and assessment axes. Full-cohort and prior-gout-excluded analyses, first diagnoses, recurrent attacks and urate are distinguished. No new incidence rates, effects, intervals, person-years, participant totals or dosing guidance are created.
- Remaining uncertainty: Exact dose, formulation, actual exposure, dosing and follow-up, event ascertainment, self-report, date imputation, missingness, censoring, models, prespecification, replication and harm details remain unverified. Historical accounts are not converted into external reading or completed clinical review in this work.
- Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, populations and events, denominators, precision and harms.
- Related sources: S01, S02

## Evidence and sources

### S01

Juraschek et al. 2022 · post hoc PHS II gout analysis

[Official source](https://pmc.ncbi.nlm.nih.gov/articles/PMC9437983/)

Materials actually read: Stored summary read; external materials unread  
Findings recorded in the summary: Selected prior-gout-excluded262/6865 versus290/6823; HR0.90(95%CI0.76–1.07),P=.23; rates4.8 versus5.4/1000 person-years. Full-cohort454/7329 versus517/7312; HR0.88(95%CI0.77–0.99),P=.04 is separate context.  
Record level: Original total14,641, C7329/placebo7312, male physicians≥50 years and6.5% prior gout are distinguished from the prior-gout-excluded6865/6823. Annual self-reported diagnoses, date imputation and post hoc selection have limitations; exact dose, duration, model and harm details remain unverified.  
Independent replication: The full-cohort and prior-gout-excluded PHS II results are analyses of the same original factorial trial, not independent replications. The chronic-gout review is distinguished as parent bibliographic context. Unique trial, participant and replication totals remain unverified.

| Material | Public availability | Access status | Actually read | Notes |
|---|---|---|---|---|
| Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| External paper | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Protocol | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Statistical analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Funding, product support and COI material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID35575611, PMCIDPMC9437983, DOI10.1093/ajcn/nqac140 and NCT00270647 are retained. The registration identifier is an original-trial citation record; official gout prespecification and current original-text reading remain unverified. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |

### S02

Dietary interventions for chronic gout · Cochrane 2021

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34767649/)

Materials actually read: Stored summary read; external materials unread  
Findings recorded in the summary: The existing citation records that the vitamin C trials did not measure gout-attack frequency.  
Record level: This is parent flare-verdict bibliographic context, PMID34767649. It is not repurposed as a new direct trial, new participants or a urate value for first diagnosis in men without gout.  
Independent replication: The full-cohort and prior-gout-excluded PHS II results are analyses of the same original factorial trial, not independent replications. The chronic-gout review is distinguished as parent bibliographic context. Unique trial, participant and replication totals remain unverified.

| Material | Public availability | Access status | Actually read | Notes |
|---|---|---|---|---|
| Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| External paper | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Protocol | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Statistical analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |
| Funding, product support and COI material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | This is the existing bibliography for PMID34767649. External abstracts, full text and review inclusion/extraction materials are unread; it is not elevated to direct first-diagnosis evidence. Dates for all material slots are the original record’s historical evidence date. Unread external slots retain the same historical date, which is not presented as current external reading. |

## Review criteria and methods

These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score.

- M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
- M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
- M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
- M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
- M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

## What the statuses mean

- Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
- Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
- Review incomplete: Review of existing content remains incomplete.
- Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
- Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
- Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
- Not applicable: Used only with an application exception and reason based on the question scope.
- Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
- Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

## Change history

2026-10-22 · Public page/materials 1.0. Public-facing views and materials were prepared from the existing 26 items. No new clinical search, verification-status change or scoring was performed.